News | February 21, 2022
Corbevax receives EUA for 12-18 age group
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
The recommendation has been sent to the DCGI for approval
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Subscribe To Our Newsletter & Stay Updated
